NCT03982134View on ClinicalTrials.gov

PDR001 + Panobinostat for Melanoma and NSCLC

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

September 30, 2019

Primary Completion Date

May 1, 2021

Study Completion Date

May 1, 2022

Conditions

MelanomaNon Small Cell Lung Cancer

Interventions

DRUG

PDR001

PDR001 is a humanized IgG4 antibody

DRUG

Panobinostat

Panobinostat is a Histone deacetylase inhibitor (HDACi).

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Muhammad Furqan

OTHER